Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HDIT101 versus valaciclovir in chronic recurrent anogenital HSV-2 infection
2019-000880-26Phase 2Completed
- Sponsor
- Heidelberg ImmunoTherapeutics
- Start
- May 2019
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Genital Herpes Type 2 (HSV-2) and genital herpes comparing HDIT101 single dose with Valtrex episodic standard of care (2 arms). Primary endpoint: Percentage of days with lesion(s). Started May 2019; status: completed.
02
Drugs
HDIT101valaciclovir
03
Conditions
Genital Herpes Type 2 (HSV-2)genital herpes
Beyond the preview
Go deeper on 2019-000880-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000880-26.